The company received a notice of allowance from the U.S. Patent and Trademark Office for Exparel’s chemical composition, according to a news release. Pacira plans to submit the patent for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations.
Pacira also received a notice of allowance from the USPTO for a patent relating to a novel manufacturing process for Exparel.
Both patents will have an expiration date of Jan. 22, 2041.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
